Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.
about
Patient's Natural Killer Cells in the Era of Targeted Therapies: Role for Tumor Killers.Natural killer cell activity for IFN-gamma production as a supportive diagnostic marker for gastric cancer.Regulation of mTOR, Metabolic Fitness, and Effector Functions by Cytokines in Natural Killer Cells.Natural killer cells and tumor metastasis.Peripheral White Blood Cell Subsets in Metastatic Colorectal Cancer Patients Treated with Cetuximab: The Potential Clinical Relevance.In vitro immunotherapy potency assays using real-time cell analysis.Characterization of the interaction between human decidua parietalis mesenchymal stem/stromal cells and natural killer cells.High neutrophil to lymphocyte ratio and decreased CD69+NK cells represent a phenotype of high risk in early-stage breast cancer patients.Next generation immune-checkpoints for cancer therapy.Altered NKp30, NKp46, NKG2D, and DNAM-1 Expression on Circulating NK Cells Is Associated with Tumor Progression in Human Gastric Cancer
P2860
Q42209070-4D44B7ED-4CDA-4263-A4AF-B9D3B2169D42Q42378441-E8A251A6-9DB0-4127-81E3-2868478FF209Q43166710-386D9D7B-3CA1-4112-910B-5E16BDB85F2AQ48130583-0F11C443-ECF1-49D0-BA4B-2AF2824FB48CQ49295280-DB7F0E63-33D0-4321-8D52-FE3EE1C88691Q52369403-ADE0A130-28A9-41E1-A772-511DA241E1D8Q52719759-F089F8B7-D260-487E-9353-19868C59580EQ55283234-E20E3F49-2476-4FC7-B586-70B8CD5A3B69Q55383705-E0DC2AB7-7D99-4D90-A6F7-F984BC12A000Q58766803-52FDEAC0-44E6-4647-9190-AFE510D20F32
P2860
Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phenotypic and Functional Dysr ...... Cetuximab Plus IL-2 or IL-15.
@en
Phenotypic and Functional Dysr ...... Cetuximab Plus IL-2 or IL-15.
@nl
type
label
Phenotypic and Functional Dysr ...... Cetuximab Plus IL-2 or IL-15.
@en
Phenotypic and Functional Dysr ...... Cetuximab Plus IL-2 or IL-15.
@nl
prefLabel
Phenotypic and Functional Dysr ...... Cetuximab Plus IL-2 or IL-15.
@en
Phenotypic and Functional Dysr ...... Cetuximab Plus IL-2 or IL-15.
@nl
P2093
P2860
P356
P1476
Phenotypic and Functional Dysr ...... Cetuximab Plus IL-2 or IL-15.
@en
P2093
Alejandro Pairola
Eduardo Huertas
Estefanía Paula Juliá
Estrella Mariel Levy
Fernando Sánchez Loria
José Mordoh
Luisina Bruno
María Betina Pampena
María Paula Roberti
Sergio Rivero
P2860
P356
10.3389/FIMMU.2016.00413
P577
2016-10-10T00:00:00Z